• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Efficacy and Prognosis of Adjuvant Argatroban Treatment in Acute Ischemic Stroke Patients with Early Neurological Deterioration
CONCLUSIONS: Aspirin combined with argatroban significantly improved neurological impairment of AIS patients with END, which is worthy of clinical application.PMID:37105928 | DOI:10.24976/Discov.Med.202335175.19
Source: Discovery Medicine - April 27, 2023 Category: Research Authors: Shu Xu Wenjun Zhang Yan Zhang Zhou Xu Ting Wu Source Type: research

Id: 24: benefits and risks of warfarin with and without aspirin in patients with coronary artery disease or cerebrovascular accident: a meta-analysis of randomized controlled trials
Conclusions Use of intermediate intensity warfarin with aspirin reduced the risk of stroke at the price of increased bleeding. Most anticoagulation increased the risk of major bleeding with no effect on mortality. Studies with oral anticoagulants with aspirin for secondary prevention should be considered.
Source: Journal of Investigative Medicine - March 21, 2016 Category: Research Authors: Deshpande, A., Patel, K., Rothberg, M., Pasupuleti, V., Alreja, G., Katzan, I. Tags: Epidemiology/Health Care Outcomes/Quality Improvement/Bioinformatics Source Type: research

Combination anticoagulant or P2Y12 inhibitor with low-dose aspirin versus low-dose aspirin alone in patients at risk or with documented coronary and/or peripheral artery disease
CONCLUSIONS: Compared to clopidogrel + low dose aspirin, the use of rivaroxaban 2.5 mg twice daily + low dose aspirin reduced the risk of MACE, CV death and stroke including ischemic stroke in patients with or at high risk for chronic CAD and/or PAD. These benefits of rivaroxaban 2.5 mg twice daily + low dose aspirin compared to clopidogrel + low-dose aspirin appear to be achieved without significantly increasing patients' risk of moderate-to-severe including ICH or fatal bleeding.PMID:34641745 | DOI:10.1080/03007995.2021.1991294
Source: Current Medical Research and Opinion - October 13, 2021 Category: Research Authors: Craig I Coleman Akshay A Kharat Brahim Bookhart William L Baker Source Type: research

Safety and Efficacy of Triple Antithrombotic Therapy with Dabigatran versus Vitamin K Antagonist in Atrial Fibrillation Patients: A Pilot Study.
Conclusion: Dabigatran at the dose used for stroke prevention appears safer than VKA and maintains a similar efficacy profile, when used with DAPT, in AF patients who have undergone PCI with stenting for ACS. PMID: 30895193 [PubMed - in process]
Source: Biomed Res - March 22, 2019 Category: Research Authors: Russo V, Rago A, Proietti R, Attena E, Rainone C, Crisci M, Papa AA, Calabrò P, D'Onofrio A, Golino P, Nigro G Tags: Biomed Res Int Source Type: research

Methodologies for pragmatic and efficient assessment of benefits and harms: Application to the SOCRATES trial.
CONCLUSION: Ordinal outcomes can improve efficiency through required pre-specification, careful construction, and analyses. Greater pragmatism can be obtained by composing outcomes within patients. Desirability of outcome ranking provides a global assessment of the benefits and harms that more closely reflect the experience of patients. The desirability of outcome ranking probability, the proportion in favor of treatment, the win ratio, and partial credit can more optimally inform patient treatment, enhance the understanding of the totality of intervention effects on patients, and potentially provide efficiencies over stan...
Source: Clinical Trials - July 14, 2020 Category: Research Authors: Evans SR, Knutsson M, Amarenco P, Albers GW, Bath PM, Denison H, Ladenvall P, Jonasson J, Easton JD, Minematsu K, Molina CA, Wang Y, Wong KL, Johnston SC Tags: Clin Trials Source Type: research

A hybrid automated event adjudication system for clinical trials
CONCLUSION: The automated event adjudication system in combination with human adjudicators provides a streamlined and efficient approach to event adjudication in clinical trials. To immediately apply automated event adjudication, one can first consider the automated event adjudication system and involve human assistance for cases unconfirmed by the former.PMID:36734212 | DOI:10.1177/17407745221149222
Source: Clinical Trials - February 3, 2023 Category: Research Authors: Fei Yuan Jackie Bosch John Eikelboom Gilles R Dagenais Stuart Connolly Jane Belanger Tamara Marsden Cissy Tang Balakumar Swaminathan Martin Renters Leanne Dyal Shrikant I Bangdiwala Source Type: research

Pages: 1  2  3  4